{
  "id": "5a9da8df4e03427e73000006",
  "type": "factoid",
  "question": "What is emicizumab?",
  "ideal_answer": "ACE910 (emicizumab) is a humanized bispecific antibody recognizing factor IXa and X mimicking factor VIII function.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27405674",
    "http://www.ncbi.nlm.nih.gov/pubmed/27795538",
    "http://www.ncbi.nlm.nih.gov/pubmed/28691557",
    "http://www.ncbi.nlm.nih.gov/pubmed/27885373",
    "http://www.ncbi.nlm.nih.gov/pubmed/29042366"
  ],
  "snippets": [
    {
      "text": "Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emicizumab Prophylaxis in Hemophilia A with Inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Emicizumab prophylaxis was associated with a significantly lower rate of bleeding events than no prophylaxis among participants with hemophilia A with inhibitors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment and prevention of bleeding episodes in patients with severe haemophilia A require frequent intravenous injection of factor VIII.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27885373",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ACE910 (emicizumab) is a humanized bispecific antibody recognizing factor IXa and X mimicking factor VIII function. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27795538",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emicizumab is a bispecific antibody recognizing both the enzyme factor IXa (FIXa) and the substrate factor X (FX).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29042366",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "ACE910 (emicizumab) is a humanized bispecific antibody recognizing factor IXa and X mimicking factor VIII function."
}